ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -41 مورد

Captopril: Drug information

Captopril: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Captopril: Patient drug information" and "Captopril: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Fetal toxicity:

When pregnancy is detected, discontinue captopril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.

Brand Names: Canada
  • APO-Capto;
  • CO Captopril;
  • Noyada;
  • TEVA-Captopril
Pharmacologic Category
  • Angiotensin-Converting Enzyme (ACE) Inhibitor;
  • Antihypertensive
Dosing: Adult
Acute coronary syndrome

Acute coronary syndrome:

Non-ST elevation acute coronary syndrome:

Note: Patients should be hemodynamically stable before initiation. Use as a component of an appropriate medical regimen, which may also include antiplatelet agent(s), a beta-blocker, and a statin. Continue angiotensin-converting enzyme inhibitor therapy indefinitely for patients with concurrent diabetes, left ventricular ejection fraction ≤40%, hypertension, or stable chronic kidney disease (Ref). Dosing is based on general dosing range in manufacturer's labeling.

Oral: Initial: 6.25 mg; if tolerated, increase to 12.5 mg 3 times daily; then increase to 25 mg 3 times daily during next several days and then gradually increase over next several weeks to target dose of 50 mg 3 times daily as tolerated.

ST-elevation myocardial infarction:

Note: Patients should be hemodynamically stable before initiation. Use as a component of an appropriate medical regimen, which may also include antiplatelet agent(s), a beta-blocker, and a statin (Ref). Dosing is based on general dosing range in manufacturer's labeling.

Oral: Initial: 6.25 mg; if tolerated, increase to 12.5 mg 3 times daily; then increase to 25 mg 3 times daily during next several days and then gradually increase over next several weeks to target dose of 50 mg 3 times daily as tolerated.

Heart failure with reduced ejection fraction

Heart failure with reduced ejection fraction:

Note: If tolerated, an angiotensin II receptor-neprilysin inhibitor is generally preferred over an angiotensin-converting enzyme inhibitor (Ref).

Oral: Initial: 6.25 mg 3 times daily; increase dose (eg, double) as tolerated every ≥1 to 2 weeks to a target dose of 50 mg 3 times daily (Ref). In hospitalized patients, may titrate more rapidly as tolerated (Ref).

Hypertension, chronic

Hypertension, chronic:

Note: For patients who warrant combination therapy (BP >20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use with another appropriate agent (eg, long-acting dihydropyridine calcium channel blocker or thiazide diuretic) (Ref). For severe asymptomatic hypertension, may consider short-term use for BP lowering (eg, over hours) if there is concern that severe BP elevation will precipitate an acute cardiovascular event, such as in patients with known aortic or intracranial aneurysms (Ref).

Oral: Initial: 6.25 to 25 mg 2 to 3 times daily; for patients in an acute care setting, may titrate as frequently as every 8 hours (based on pharmacokinetic properties), as needed, up to 50 mg 3 times daily; if additional BP control is needed, consider combination therapy (Ref). In an ambulatory setting, patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication adjustment within 1 week. Consider transitioning to an appropriate longer-acting antihypertensive to improve adherence for chronic use (Ref).

Primary aldosteronism

Primary aldosteronism (diagnostic agent) (off-label use): Note: Administer after patient has been sitting or standing for at least 1 hour.

Oral: 25 to 50 mg as a single dose (Ref).

Proteinuric chronic kidney disease, diabetic or nondiabetic

Proteinuric chronic kidney disease, diabetic (labeled use) or nondiabetic (off-label use):

Oral: Initial: 12.5 to 25 mg two to three times daily depending on initial BP; titrate gradually (eg, by doubling the dose every 2 to 4 weeks) up to the maximally tolerated dose, not to exceed 50 mg three times daily. If proteinuria target is not met despite optimized dosage, consider additional therapies (eg, sodium-glucose cotransporter-2 inhibitor) (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Kidney impairment prior to treatment initiation:

Altered kidney function (Ref): Oral:

CrCl ≥50 mL/minute: No dosage adjustment necessary.

CrCl 10 to <50 mL/minute: Initial: Administer the usual indication-specific dose every 12 to 24 hours. Titrate slowly based on tolerability and response; consider a maximum dose of 50 mg every 12 hours.

CrCl <10 mL/minute: Initial: Administer the usual indication-specific dose every 24 hours. Titrate slowly based on tolerability and response; consider a maximum dose of 50 mg every 24 hours.

Hemodialysis, intermittent (thrice weekly): Dialyzable (~35%) (Ref):

Note: Avoid use if an AN69 hemofilter is used (associated with anaphylactoid reaction) (Ref).

Oral: Initial: Administer the usual indication-specific dose every 24 hours. When scheduled dose falls on a dialysis day, administer after dialysis. Titrate slowly based on tolerability and response; consider a maximum dose of 50 mg every 24 hours (Ref).

Peritoneal dialysis: Dialyzable: Oral: Initial: Administer the usual indication-specific dose every 24 hours. Titrate slowly based on tolerability and response; consider a maximum dose of 50 mg every 24 hours (Ref).

CRRT: Note: Avoid use if an AN69 hemofilter is used (associated with anaphylactoid reaction) (Ref).

Oral: Initial: Administer usual indication-specific dose every 12 to 24 hours (Ref). Titrate slowly based on tolerability and response; consider a maximum dose of 50 mg every 12 hours.

PIRRT (eg, sustained, low-efficiency diafiltration): Note: Avoid use if an AN69 hemofilter is used (associated with anaphylactoid reaction) (Ref).

Oral: Initial: Administer usual indication-specific dose every 12 to 24 hours (Ref). When scheduled dose falls on a PIRRT day, administer after PIRRT (Ref). Titrate slowly based on tolerability and response; consider a maximum dose of 50 mg every 12 hours.

Alterations in kidney function during treatment:Small, transient increases in serum creatinine are likely to occur within 4 weeks following initiation of therapy or an increase in dose. If serum creatinine increases by >30%, review for possible etiologies (eg, acute kidney injury, volume depletion, concomitant medications, renal artery stenosis) before determining if dose reduction or discontinuation of captopril therapy should be considered (Ref).

Dosing: Liver Impairment: Adult

The liver dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, FCCP; Jeong Park, PharmD, MS, BCXTP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.

Note: In general, use of angiotensin-converting enzyme inhibitors in patients with cirrhosis and ascites should be avoided as use can further diminish renal blood flow and precipitate hepatorenal syndrome (Ref). Captopril does not require liver metabolism for activation (Ref).

Liver impairment prior to treatment initiation:

Initial or dose adjustment in patients with preexisting liver cirrhosis:

Child-Turcotte-Pugh class A to C: No dosage adjustment necessary; avoid use in patients with ascites (Ref).

Dosing: Adjustment for Toxicity: Adult

Hyperkalemia: Assess for alternative or contributing factors (eg, diet, concomitant medications) of increased potassium before determining if dose reduction or discontinuation of captopril therapy should be considered (Ref).

Dosing: Older Adult

Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (Ref).

Dosing: Pediatric

(For additional information see "Captopril: Pediatric drug information")

Heart failure

Heart failure (afterload reduction): Limited data available: Note: Initiate therapy at lower end of range and titrate upward to prevent symptomatic hypotension (Ref):

Infants: Oral: Initial: 0.1 to 0.3 mg/kg/dose every 6 to 24 hours; increase as tolerated and based on clinical response; usual reported daily dose range: 0.3 to 3.5 mg/kg/day divided every 6 to 12 hours; maximum daily dose: 6 mg/kg/day (Ref).

Children: Oral: Initial: 0.3 to 0.5 mg/kg/dose every 8 to 12 hours; increase as tolerated and based on clinical response; maximum daily dose: 6 mg/kg/day (Ref); in adults, the target dose is 150 mg/day (Ref).

Adolescents: Oral: Initial: 6.25 to 12.5 mg/dose 2 to 3 times daily; increase as tolerated and based on clinical response (Ref); in adults, the target dose is 150 mg/day (Ref).

Hypertension

Hypertension: Limited data available:

Weight-directed dosing:

Infants: Oral: Initial: 0.05 mg/kg/dose every 6 to 24 hours (Ref); higher initial doses of 0.1 to 0.3 mg/kg/dose every 8 hours up to 0.5 mg/kg/dose every 8 hours have been recommended by some experts and may be needed in patients with severe hypertension (Ref); adjust dose based on blood pressure response; maximum daily dose: 6 mg/kg/day (Ref).

Children and Adolescents: Oral: Initial: 0.3 to 0.5 mg/kg/dose every 8 hours; adjust dose based on blood pressure response; maximum daily dose: 6 mg/kg/day (Ref); in adults, the dose is titrated up to 150 mg/day (usual dose) (Ref).

Fixed dosing: Adolescents: Oral: Initial: 12.5 to 25 mg/dose every 8 to 12 hours; increase by 25 mg/dose weekly based on blood pressure response; in adults, the dose is increased up to 150 mg/day (usual dose) (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Infants, Children, and Adolescents: There are no dosage recommendations in the manufacturer's labeling. The following adjustments have been recommended (Ref). Note: Renally adjusted dose recommendations are based on doses of 0.1 to 0.5 mg/kg/dose every 6 to 8 hours; maximum daily dose: 6 mg/kg/day.

GFR 10 to 50 mL/minute/1.73 m2: Administer 75% of dose.

GFR <10 mL/minute/1.73 m2: Administer 50% of dose.

Intermittent hemodialysis: Administer 50% of dose.

Peritoneal dialysis (PD): Administer 50% of dose.

Continuous renal replacement therapy (CRRT): Administer 75% of dose.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Adverse Reactions (Significant): Considerations
Acute kidney injury

Use may be associated with increased blood urea nitrogen (azotemia) and increased serum creatinine, resulting in oliguria and acute kidney injury (AKI) in all ages. Increases in serum creatinine are expected due to pharmacologic mechanism and generally stabilize within 20% to 30% of the baseline; higher increases may indicate high efferent tone (such as with hypovolemia, congestive heart failure, or renal artery stenosis) (Ref).

Mechanism: Related to pharmacologic action; inhibits efferent arteriolar vasoconstriction, which can lead to a reduction in the glomerular filtration rate (GFR). Kidney hypoperfusion from systemic hypotension may also occur (Ref).

Onset: Intermediate; increases in serum creatinine generally occur within 2 weeks of initiation and stabilize within 2 to 4 weeks (Ref). However, more immediate increases can occur in patients with other risk factors for AKI (Ref).

Risk factors:

• Patients with low renal blood flow whose GFR is dependent on efferent arteriolar vasoconstriction by angiotensin II (Ref):

- Low effective circulating volume (sodium or volume depletion)

- Congestive heart failure

- Hypotension or shock

- Renal artery stenosis

• High dose at initiation (Ref)

• Age

- Neonates; risk may be higher in preterm neonates (Ref)

- Older adults (Ref)

• Preexisting kidney impairment (Ref)

• Concurrent diuretic and/or nonsteroidal anti-inflammatory drug use (Ref)

Angioedema

Angioedema may occur rarely; edema may manifest in the head and neck (potentially compromising airway) or the intestine (presenting as abdominal pain). Use is contraindicated in patients with idiopathic or hereditary angioedema or previous angioedema associated with any angiotensin-converting enzyme inhibitors or neprilysin inhibitors (Ref).

Mechanism: Related to pharmacologic action (ie, increased bradykinin and substance P, vascular permeability, vasodilation) (Ref).

Onset: Varied; may occur at any time during treatment. Most cases occur within the first week of therapy but may also occur years after therapy (Ref).

Risk factors:

• Black patients (estimated 4- to 5-fold higher risk); the mechanism for this is not completely understood but may be related to genetic variants) (Ref)

• Females (Ref)

• Smoking history (Ref)

• Previous history of angioedema (Ref)

• Age >65 years (Ref)

• Seasonal allergies (Ref)

• Concurrent use of mechanistic target of rapamycin (mTOR) inhibitors (eg, everolimus) (Ref)

• Concurrent use of neprilysin inhibitor (contraindicated)

Cough

A dry, hacking, nonproductive cough that is typically associated with tickling or scratching in the throat may occur with angiotensin-converting enzyme inhibitors (ACEI) in adult and pediatric patients (Ref). Recurrence is likely with rechallenge (Ref). Resolution of cough typically occurs 1 to 4 weeks after ACEI discontinuation but may persist for up to 3 months (Ref).

Mechanism: Various proposed mechanisms. May be related to pharmacologic action (increase in bradykinin and substance P, resulting in accumulation in the lungs and bronchoconstriction) (Ref).

Onset: Varied; within hours to 4 weeks after initiation but can be delayed for up to 6 months (Ref).

Risk factors:

• Females (Ref)

• Possibly certain genetic variants (some of which may be independent of the bradykinin pathway) (Ref)

Dermatologic reactions

Various cutaneous reactions have been reported, including skin rash (Ref) and rarer events, such as toxic epidermal necrolysis (Ref), lichenoid eruption (Ref), drug rash with eosinophilia and systemic symptoms (DRESS) (Ref), linear IgA bullous dermatosis (LABD) (Ref), and pemphigus (Ref). Skin rash is often transitory, lasting for hours or days and may resolve upon continued therapy with captopril (Ref). Skin photosensitivity has also been described (Ref).

Mechanism:

Skin rash: Not well described; may be dose-related (ie, enhances cutaneous histamine reaction) (Ref) or non–dose-related.

Pemphigus: Unknown, but the sulfhydryl group found in captopril may cause biochemical modifications of antigens or bind to desmosomal proteins, resulting in autoantibody formation (Ref).

Delayed hypersensitivity reactions including TEN and DRESS: Non–dose-related; immunologic (ie, involving a T-cell mediated drug-specific immune response) (Ref).

Onset:

Skin rash: Can occur in the first few weeks of treatment, although most cases occur within the first few days (Ref).

Lichenoid eruptions: May occur up to 2 years after captopril initiation (Ref). The mean time interval between initiation of captopril and pemphigus onset was ~6 months (Ref).

Delayed hypersensitivity reactions including DRESS and TEN: Varied; typically 1 to 8 weeks after drug exposure (Ref), although may occur within days (Ref).

Risk factors:

• Skin rash:

- High doses (Ref)

- Kidney impairment (Ref)

• Cross-reactions with other angiotensin-converting enzyme inhibitors not consistent (Ref)

Hematologic effects

Rare but serious bone marrow suppression with decreases in hematological cell lines have occurred in patients taking captopril, which can manifest as neutropenia (Ref), agranulocytosis (Ref), thrombocytopenia (Ref), hemolytic anemia (Ref), or pancytopenia (Ref). Most cases have been reported in adults; a few pediatric cases have been reported (Ref). Some reported cases have been fatal (Ref), whereas in other cases, bone marrow recovery occurred after captopril reintroduction without incident (Ref). Reports of bone marrow suppression appear to be more common in patients taking captopril than in patients taking other angiotensin-converting enzyme inhibitors (Ref). Due to the infrequency of reports on bone marrow suppression and the low-quality of the available evidence, a causal relationship between captopril and hematologic effects has not been demonstrated. Neutrophil count generally returns to baseline within 2 weeks of discontinuation.

Mechanism: Unknown, likely idiosyncratic. Postulated mechanisms for bone marrow suppression include an immune-mediated reaction against bone marrow precursor cells or a direct toxic effect of reactive metabolites on blood cells and precursors (Ref).

Onset: Neutropenia: Varied; usually within 3 months of initiation.

Risk factors:

• High captopril doses ≥150 mg/day (Ref)

• Baseline kidney dysfunction, including renal transplantation (Ref)

• Concurrent immunosuppressive drugs (Ref)

• Connective tissue disorders such as systemic lupus erythematosus and scleroderma (Ref)

• Patients with Trisomy 21 may be at increased risk (Ref)

Hyperkalemia

Hyperkalemia (elevated serum potassium) may occur on therapy with angiotensin-converting enzyme inhibitors (ACEI), including captopril (Ref).

Mechanism: Related to pharmacologic action; inhibits formation of circulating angiotensin II, which leads to efferent arteriole vasodilation and subsequent lowering of glomerular filtration rate, which lowers potassium elimination. Additionally, interferes with the generation and release of aldosterone from the adrenal cortex, leading to an impairment of potassium excretion from the kidney (Ref).

Risk factors:

• Disease states associated with hyperkalemia (congestive heart failure, diabetes mellitus, chronic kidney disease) (Ref)

• Concurrent use of medications which cause hyperkalemia (ACEI, angiotensin II receptor antagonists, spironolactone, nonsteroidal anti-inflammatory drugs, beta blockers, heparin, tacrolimus, cyclosporine) (Ref)

• Acute kidney injury (elevated BUN and/or serum creatinine) (Ref)

• High dietary intake of potassium or concomitant use of potassium supplements (including potassium-containing salt substitutes) (Ref)

• Baseline elevated potassium level (≥5 mmol/L) (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Cardiovascular: Chest pain (1%), palpitations (1%), tachycardia (1%)

Dermatologic: Alopecia (≤2%), pruritus (2%), skin rash (4% to 7%; including maculopapular rash, urticaria; in patients with rash, a positive ANA and/or eosinophilia has been noted in 7% to 10%)

Gastrointestinal: Abdominal pain (≤2%), ageusia (≤4%), anorexia (≤2%), aphthous stomatitis (≤2%), constipation (≤2%), diarrhea (≤2%), dysgeusia (≤4%; diminished taste perception), gastric irritation (≤2%), nausea (≤2%), peptic ulcer (≤2%), vomiting (≤2%), xerostomia (≤2%)

Genitourinary: Proteinuria (≤1%)

Hematologic & oncologic: Neutropenia (in patients with or without renal impairment with no collagen vascular disease: <1%; in patients with impaired renal function and collagen vascular disease [eg, systemic lupus erythematous, scleroderma]: 4%)

Nervous system: Dizziness (≤2%), fatigue (≤2%), headache (≤2%), insomnia (≤2%), malaise (≤2%), paresthesia (≤2%)

Respiratory: Cough (≤2%), dyspnea (≤2%)

<1%:

Cardiovascular: Acute myocardial infarction, angina pectoris, cardiac failure, flushing, Raynaud's disease

Dermatologic: Pallor

Genitourinary: Nephrotic syndrome, oliguria, urinary frequency

Hypersensitivity: Angioedema

Renal: Acute kidney injury, polyuria, renal insufficiency

Frequency not defined:

Cardiovascular: Hypotension

Hematologic & oncologic: Anemia, aplastic anemia,

Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases

Renal: Increased blood urea nitrogen, increased serum creatinine

Postmarketing:

Cardiovascular: Cardiac arrhythmia, cerebrovascular accident, cerebrovascular insufficiency, orthostatic hypotension, syncope

Dermatologic: Bullous pemphigoid, bullous skin disease (Friedman 1998), dermatitis (Martinez 2011), dermatologic disorder (linear IgA bullous dermatosis) (Friedman 1998), erythema multiforme, exfoliative dermatitis (Solinger 1982), lichenoid eruption (Ben Salem 2008), pemphigus (Ghaedi 2021), skin photosensitivity (Hofmann 2021), Stevens-Johnson syndrome, toxic epidermal necrolysis (Alkurtass 2003)

Endocrine & metabolic: Gynecomastia (Markusse 1988), hyperkalemia (Weir 2010), hyponatremia (symptomatic)

Gastrointestinal: Cholestasis (Kocab 2000), dyspepsia, glossitis, pancreatitis (Gorsane 2019)

Genitourinary: Impotence, membranous glomerulonephritis (Bailey 1992)

Hematologic & oncologic: Agranulocytosis (Suarez 1986), eosinophilia, hemolytic anemia (Trimble 2007), pancytopenia (Chisi 1999), positive ANA titer, thrombocytopenia (Kramer 1983)

Hepatic: Hepatic necrosis (rare), hepatitis (Vandenburg 1981), jaundice (Crantock 1991)

Hypersensitivity: Nonimmune anaphylaxis (Peces 2002)

Immunologic: Drug reaction with eosinophilia and systemic symptoms (Ammar 2019)

Nervous system: Ataxia, confusion, depression, drowsiness, myasthenia, nervousness, seizure (in infants) (Perlman 1989), visual hallucination (Doane 2013)

Neuromuscular & skeletal: Asthenia, myalgia

Ophthalmic: Blurred vision

Respiratory: Bronchospasm, eosinophilic pneumonitis, rhinitis

Contraindications

Hypersensitivity to captopril, any other angiotensin-converting enzyme (ACE) inhibitor, or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; concomitant use with aliskiren in patients with diabetes mellitus; coadministration with or within 36 hours of switching to or from a neprilysin inhibitor (eg, sacubitril).

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Canadian labeling: Additional contraindications (not in US labeling): Concomitant use with aliskiren in patients with moderate to severe kidney impairment (GFR <60 mL/minute/1.73 m2).

Oral solution: Additional contraindications: Hereditary or idiopathic angioedema; pregnancy; patients of childbearing potential; hemodynamically significant bilateral renal artery stenosis; severe stenosis of the artery of a single functioning kidney.

Warnings/Precautions

Concerns related to adverse effects:

• Cholestatic jaundice: A rare toxicity includes cholestatic jaundice, which may progress to fulminant hepatic necrosis (some fatal); discontinue if marked elevation of hepatic transaminases or jaundice occurs.

• Hypersensitivity reactions: Anaphylactic reaction/nonimmune anaphylaxis can occur with angiotensin-converting enzyme (ACE) inhibitors. Severe nonimmune anaphylaxis may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low-density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of nonimmune anaphylaxis have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.

• Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses). Effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation. Close monitoring of patient is required especially with initial dosing and dosing increases; BP must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use, especially in patients with heart failure where a reduction in systolic BP is a desirable observation.

• Proteinuria: Total urinary proteins >1 g per day have been reported (<1%); nephrotic syndrome occurred in about one-fifth of proteinuric patients. In most cases, proteinuria subsided or cleared within 6 months (whether or not captopril was continued).

Disease-related concerns:

• Aortic stenosis: Use with caution in patients with aortic stenosis; may reduce coronary perfusion resulting in ischemia.

• Ascites: Generally, avoid use in patients with ascites due to cirrhosis or refractory ascites; if use cannot be avoided in patients with ascites due to cirrhosis, monitor BP and kidney function carefully to avoid rapid development of kidney failure (AASLD [Runyon 2013]).

• Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling BP (eg, myocardial infarction [MI], stroke). Fluid replacement, if needed, may restore BP; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs. In a retrospective cohort study of elderly patients (≥65 years of age) with MI and impaired left ventricular function, administration of an ACE inhibitor was associated with a survival benefit, including patients with serum creatinine concentrations >3 mg/dL (265 micromol/L) (Frances 2000).

• Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant kidney impairment; may be at increased risk for hematologic toxicity.

• Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: Use with caution in patients with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (AHA/ACC [Ommen 2024]).

• Kidney impairment: Use with caution in preexisting kidney insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation, which may lead to further kidney impairment.

Special populations:

• Race/Ethnicity: Some studies suggest that when used as monotherapy for hypertension, the BP-lowering effects of renin-angiotensin system (RAS) inhibitors (eg, ACE inhibitors) may be somewhat less pronounced in Black patients (ACC/AHA [Whelton 2018]). The mechanism is not known but may be related to social determinants of health rather than race, as pharmacogenetic differences have not been found to adequately predict BP response (Brewster 2013; Gardner 2022). These observed BP differences were not apparent when RAS inhibitors were used as part of combination therapy (eg, combined with a calcium channel blocker or thiazide diuretic) (Jamerson 2008). Drug selection should be individualized and based on multiple patient-specific factors and not purely race/ethnicity (Holt 2022).

• Surgery: In patients on chronic ACE inhibitor therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia. Cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension; however, discontinuation of therapy prior to surgery is controversial. If continued preoperatively, avoidance of hypotensive agents during surgery is prudent (Hillis 2011). In patients undergoing elevated-risk noncardiac surgery who take an ACE inhibitor for hypertension, it is reasonable to hold treatment 24 hours before surgery to limit intraoperative hypotension then restart postoperatively as soon as clinically feasible. In patients who take an ACE inhibitor for heart failure, it is reasonable to continue therapy, uninterrupted, perioperatively (AHA/ACC [Thompson 2024]).

Other warnings/precautions:

• Extemporaneous oral solutions: Extemporaneous preparations of liquid formulations may vary; this may affect the rate and extent of absorption causing intrapatient variability regarding dosing and safety profile for the patient; use with caution and monitor closely if dosage formulations are changed (Bhatt 2011; Mulla 2007).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 12.5 mg, 25 mg, 50 mg, 100 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Captopril Oral)

12.5 mg (per each): $1.56 - $1.70

25 mg (per each): $1.27 - $1.80

50 mg (per each): $2.90

100 mg (per each): $3.81

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Oral:

Noyada: 1 mg/mL (100 mL); 5 mg/mL (100 mL) [contains edetate (edta) disodium, sodium benzoate]

Tablet, Oral:

Generic: 6.25 mg [DSC], 12.5 mg, 25 mg, 50 mg, 100 mg

Administration: Adult

Oral: Administer at least 1 hour before meals. Unstable in aqueous solutions; to prepare solution for oral administration, mix prior to administration and use within 10 minutes (Ref).

Administration: Pediatric

Oral: Administer on an empty stomach 1 hour before or 2 hours after meals/feeds; administration with food will decrease absorption; consistent administration times are recommended (Ref). If crushing tablet and dissolving in water, allow adequate time for complete dissolution (>10 minutes) (Ref); may also prepare and administer as an extemporaneous oral liquid.

Use: Labeled Indications

Acute coronary syndrome: To improve survival following myocardial infarction (MI) (eg, ST-elevation MI or non-ST-elevation MI) in clinically stable patients, including those with left ventricular dysfunction manifested as an ejection fraction of ≤40%.

Heart failure with reduced ejection fraction: Treatment of heart failure.

Hypertension, chronic: Management of hypertension.

Proteinuric chronic kidney disease, diabetic: Treatment of diabetic nephropathy (proteinuria >500 mg/day) in patients with type 1 insulin-dependent diabetes mellitus and retinopathy.

Use: Off-Label: Adult

Aldosteronism, primary (diagnostic test); Proteinuric chronic kidney disease, nondiabetic

Medication Safety Issues
Sound-alike/look-alike issues:

Captopril may be confused with calcitriol, Capitrol, carvedilol.

International issues:

Acepril [Great Britain] may be confused with Accupril which is a brand name for quinapril in the US.

Acepril: Brand name for captopril [Great Britain], but also the brand name for enalapril [Hungary, Switzerland]; lisinopril [Malaysia].

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Alfuzosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Aliskiren: May increase hyperkalemic effects of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may increase nephrotoxic effects of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may increase hypotensive effects of Angiotensin-Converting Enzyme Inhibitors. Management: Aliskiren use with ACEIs or ARBs in patients with diabetes is contraindicated. Combined use in other patients should be avoided, particularly when CrCl is less than 60 mL/min. If combined, monitor potassium, creatinine, and blood pressure closely. Risk D: Consider Therapy Modification

Allopurinol: Angiotensin-Converting Enzyme Inhibitors may increase hypersensitivity effects of Allopurinol. Risk C: Monitor

Alteplase: Angiotensin-Converting Enzyme Inhibitors may increase adverse/toxic effects of Alteplase. Specifically, the risk for angioedema may be increased. Risk C: Monitor

Amifostine: Blood Pressure Lowering Agents may increase hypotensive effects of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider Therapy Modification

Amphetamines: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Angiotensin II Receptor Blockers: May increase adverse/toxic effects of Angiotensin-Converting Enzyme Inhibitors. Angiotensin II Receptor Blockers may increase serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: Use of telmisartan and ramipril is not recommended. It is not clear if any other combination of an ACE inhibitor and an ARB would be any safer. Consider alternatives when possible. Monitor blood pressure, renal function, and potassium if combined. Risk D: Consider Therapy Modification

Angiotensin II: Angiotensin-Converting Enzyme Inhibitors may increase therapeutic effects of Angiotensin II. Risk C: Monitor

Antacids: May decrease serum concentration of Captopril. Risk C: Monitor

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may increase hypotensive effects of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor

Aprotinin: May decrease antihypertensive effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Arginine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

AzaTHIOprine: Angiotensin-Converting Enzyme Inhibitors may increase myelosuppressive effects of AzaTHIOprine. Risk C: Monitor

Barbiturates: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Benperidol: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Beta-Acetyldigoxin: Captopril may increase serum concentration of Beta-Acetyldigoxin. Risk C: Monitor

Brigatinib: May decrease antihypertensive effects of Antihypertensive Agents. Brigatinib may increase bradycardic effects of Antihypertensive Agents. Risk C: Monitor

Brimonidine (Topical): May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Bromperidol: May decrease hypotensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase hypotensive effects of Bromperidol. Risk X: Avoid

Dapoxetine: May increase orthostatic hypotensive effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Dexmethylphenidate: May decrease therapeutic effects of Antihypertensive Agents. Risk C: Monitor

Diazoxide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Dipeptidyl Peptidase-IV Inhibitors: May increase adverse/toxic effects of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased. Risk C: Monitor

Drospirenone-Containing Products: May increase hyperkalemic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

DULoxetine: Blood Pressure Lowering Agents may increase hypotensive effects of DULoxetine. Risk C: Monitor

Everolimus: May increase adverse/toxic effects of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased. Risk C: Monitor

Ferric Gluconate: Angiotensin-Converting Enzyme Inhibitors may increase adverse/toxic effects of Ferric Gluconate. Risk C: Monitor

Ferric Hydroxide Polymaltose Complex: Angiotensin-Converting Enzyme Inhibitors may increase adverse/toxic effects of Ferric Hydroxide Polymaltose Complex. Specifically, the risk for angioedema or allergic reactions may be increased. Risk C: Monitor

Finerenone: Angiotensin-Converting Enzyme Inhibitors may increase hyperkalemic effects of Finerenone. Risk C: Monitor

Flunarizine: May increase therapeutic effects of Antihypertensive Agents. Risk C: Monitor

Gelatin (Succinylated): Angiotensin-Converting Enzyme Inhibitors may increase adverse/toxic effects of Gelatin (Succinylated). Specifically, the risk of a paradoxical hypotensive reaction may be increased. Risk C: Monitor

Grass Pollen Allergen Extract (5 Grass Extract): Angiotensin-Converting Enzyme Inhibitors may increase adverse/toxic effects of Grass Pollen Allergen Extract (5 Grass Extract). Specifically, ACE inhibitors may increase the risk of severe allergic reaction to Grass Pollen Allergen Extract (5 Grass Extract). Risk X: Avoid

Heparin: May increase hyperkalemic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Heparins (Low Molecular Weight): May increase hyperkalemic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Herbal Products with Blood Pressure Increasing Effects: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Herbal Products with Blood Pressure Lowering Effects: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Hypotension-Associated Agents: Blood Pressure Lowering Agents may increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor

Icatibant: May decrease antihypertensive effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Iloperidone: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Indoramin: May increase hypotensive effects of Antihypertensive Agents. Risk C: Monitor

Iron Dextran Complex: Angiotensin-Converting Enzyme Inhibitors may increase adverse/toxic effects of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions. Risk C: Monitor

Isocarboxazid: May increase antihypertensive effects of Antihypertensive Agents. Risk X: Avoid

Lanthanum: May decrease serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: Administer angiotensin-converting enzyme (ACE) inhibitors at least two hours before or after lanthanum. Risk D: Consider Therapy Modification

Levodopa-Foslevodopa: Blood Pressure Lowering Agents may increase hypotensive effects of Levodopa-Foslevodopa. Risk C: Monitor

Lithium: Angiotensin-Converting Enzyme Inhibitors may increase serum concentration of Lithium. Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor. Monitor for increased concentrations/toxic effects of lithium if an ACE inhibitor is initiated/dose increased, or if switching between ACE inhibitors. Risk D: Consider Therapy Modification

Loop Diuretics: May increase hypotensive effects of Angiotensin-Converting Enzyme Inhibitors. Loop Diuretics may increase nephrotoxic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Lormetazepam: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Metergoline: May decrease antihypertensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase orthostatic hypotensive effects of Metergoline. Risk C: Monitor

Methylphenidate: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Molsidomine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Naftopidil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nicergoline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nicorandil: May increase hyperkalemic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Nicorandil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nitroprusside: Blood Pressure Lowering Agents may increase hypotensive effects of Nitroprusside. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents (Topical): May decrease therapeutic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents: May decrease antihypertensive effects of Angiotensin-Converting Enzyme Inhibitors. Angiotensin-Converting Enzyme Inhibitors may increase adverse/toxic effects of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Risk C: Monitor

Obinutuzumab: May increase hypotensive effects of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider Therapy Modification

Pentoxifylline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Perazine: May increase hypotensive effects of Antihypertensive Agents. Risk C: Monitor

Pholcodine: Blood Pressure Lowering Agents may increase hypotensive effects of Pholcodine. Risk C: Monitor

Phosphodiesterase 5 Inhibitors: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Polyethylene Glycol-Electrolyte Solution: Angiotensin-Converting Enzyme Inhibitors may increase nephrotoxic effects of Polyethylene Glycol-Electrolyte Solution. Risk C: Monitor

Potassium Salts: May increase hyperkalemic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Potassium-Sparing Diuretics: May increase hyperkalemic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Prazosin: Antihypertensive Agents may increase hypotensive effects of Prazosin. Risk C: Monitor

Pregabalin: Angiotensin-Converting Enzyme Inhibitors may increase adverse/toxic effects of Pregabalin. Specifically, the risk of angioedema may be increased. Risk C: Monitor

Prostacyclin Analogues: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Quinagolide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Racecadotril: May increase adverse/toxic effects of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk for angioedema may be increased with this combination. Risk C: Monitor

Ranolazine: May increase adverse/toxic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Sacubitril: Angiotensin-Converting Enzyme Inhibitors may increase adverse/toxic effects of Sacubitril. Specifically, the risk of angioedema may be increased with this combination. Risk X: Avoid

Salicylates: May decrease therapeutic effects of Angiotensin-Converting Enzyme Inhibitors. Salicylates may increase nephrotoxic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Silodosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Sirolimus Products: May increase adverse/toxic effects of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk for angioedema may be increased. Risk C: Monitor

Sodium Phosphates: Angiotensin-Converting Enzyme Inhibitors may increase nephrotoxic effects of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. Risk C: Monitor

Sparsentan: May increase adverse/toxic effects of Angiotensin-Converting Enzyme Inhibitors. Risk X: Avoid

Tacrolimus (Systemic): Angiotensin-Converting Enzyme Inhibitors may increase hyperkalemic effects of Tacrolimus (Systemic). Risk C: Monitor

Temsirolimus: May increase adverse/toxic effects of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased. Risk C: Monitor

Terazosin: Antihypertensive Agents may increase hypotensive effects of Terazosin. Risk C: Monitor

Thiazide and Thiazide-Like Diuretics: May increase hypotensive effects of Angiotensin-Converting Enzyme Inhibitors. Thiazide and Thiazide-Like Diuretics may increase nephrotoxic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Tolvaptan: May increase hyperkalemic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Trimethoprim: May increase hyperkalemic effects of Angiotensin-Converting Enzyme Inhibitors. Management: Consider avoiding coadministration if possible. If combined, monitor serum potassium closely, particularly for patients with other risk factors (eg, renal impairment, older age, and other medications that increase potassium. Risk X: Avoid

Urapidil: And Angiotensin-Converting Enzyme Inhibitors may interact via an unclear mechanism. Management: Avoid concomitant use of urapidil and angiotensin-converting enzyme (ACE) inhibitors. Risk D: Consider Therapy Modification

Urokinase: May increase adverse/toxic effects of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased. Risk C: Monitor

Food Interactions

Captopril serum concentrations may be decreased if taken with food. Long-term use of captopril may lead to a zinc deficiency, which can result in altered taste perception. Management: Take on an empty stomach 1 hour before or 2 hours after meals.

Reproductive Considerations

Avoid use of angiotensin-converting enzyme (ACE) inhibitor therapy in patients who may become pregnant and who are not using effective contraception (ADA 2021).

Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. ACE inhibitors are fetotoxic. Transition patients prior to conception to an agent preferred for use during pregnancy unless treatment with an ACE inhibitor is absolutely necessary (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).

When ACE inhibitors are used for the treatment of proteinuric chronic kidney disease in patients who could become pregnant, discontinue use at the first positive pregnancy test (ADA 2021; Fakhouri 2022).

ACE inhibitors are not recommended for the treatment of heart failure in patients planning to become pregnant (AHA/ACC/HFSA [Heidenreich 2022]).

Pregnancy Considerations

Captopril crosses the placenta (Hurault de Ligny 1987).

Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Exposure to an angiotensin-converting enzyme (ACE) inhibitor during the first trimester of pregnancy may be associated with an increased risk of fetal malformations (ACOG 2019; ESC [Regitz-Zagrosek 2018]). Following exposure during the second or third trimesters, drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Oligohydramnios may not appear until after an irreversible fetal injury has occurred. ACE inhibitor use during pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Monitor infants exposed to an ACE inhibitor in utero for hyperkalemia, hypotension, and oliguria. Exchange transfusions or dialysis may be required to reverse hypotension or improve renal function

Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).

ACE inhibitors should be discontinued as soon as possible once pregnancy is detected. When treatment of chronic hypertension in pregnancy is indicated, agents other than ACE inhibitors are recommended (ACOG 2019; ESC [Cífková 2020]; SOGC [Magee 2022]). Use during pregnancy should only be considered for cases of hypertension refractory to other medications (ACOG 2019). Closely monitor pregnant patients on ACE inhibitors with serial ultrasounds.

ACE inhibitors are not recommended for the treatment of heart failure or proteinuric chronic kidney disease during pregnancy (AHA/ACC/HFSA [Heidenreich 2022]; ESC [Regitz-Zagrosek 2018]; Fakhouri 2022).

Breastfeeding Considerations

Captopril is present in breast milk.

Data related to the presence of captopril in breast milk are available following maternal administration captopril 100 mg 3 times a day for 7 doses to 11 normotensive lactating patients. The mean peak milk concentration of captopril was 4.7 ng/mL. The maximum milk concentrations occurred 3.8 hours after the maternal dose. Captopril was not detected in all milk samples. Concentrations of captopril in breast milk were ~1% of those in maternal blood (Devlin 1981).

• Using a milk concentration of 4.7 ng/mL, the estimated daily infant dose via breast milk is 705 ng/kg/day providing a relative infant dose (RID) of 0.01% to 0.02% compared to an infant therapeutic dose of 3 to 6 mg/kg/day.

• In general, breastfeeding is considered acceptable when the RID of a medication is <10% (Anderson 2016; Ito 2000).

According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk of exposure to the infant and the benefits of treatment to the mother. When postpartum treatment with an angiotensin-converting enzyme (ACE) inhibitor is needed, available guidelines consider captopril to be acceptable for use in lactating patients (AHA/ACC/HFSA [Heidenreich 2022]; ESC [Cífková 2020]; WHO 2002). Avoid breastfeeding if high maternal doses of an ACE inhibitor are needed (ACOG 2019).

Monitoring Parameters

Blood pressure; BUN, serum creatinine; electrolytes (eg, potassium [especially in patients on concomitant potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts]). In patients with kidney impairment and/or collagen vascular disease, closely monitor CBC with differential for the first 3 months of therapy and periodically thereafter. If angioedema is suspected, assess risk of airway obstruction (eg, involvement of tongue, glottis, larynx, and/or history of airway surgery).

Aldosteronism, primary (diagnostic test): Plasma renin activity, plasma aldosterone, and serum cortisol levels at baseline and 1 or 2 hours after challenge; patient should remain seated during this time (ES [Funder 2016]).

Mechanism of Action

Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Within 15 minutes; Peak effect: Blood pressure reduction: 1 to 1.5 hours after dose

Maximum effect: Antihypertensive: 60 to 90 minutes; may require several weeks of therapy before full hypotensive effect is seen

Duration: Dose related, may require several weeks of therapy before full hypotensive effect

Absorption: 60% to 75%; rapid

Distribution: Vdss: 0.7 L/kg (Duchin 1982)

Bioavailability: ~60% to 75% (Kubo 1985); reduced 30% to 40% by food

Protein binding: 25% to 30%

Metabolism: 50% metabolized

Half-life elimination:

Infants with CHF: 3.3 hours; range: 1.2 to 12.4 hours (Pereira 1991)

Children: 1.5 hours; range: 0.98 to 2.3 hours (Levy 1991)

Adults, healthy volunteers: ~1.7 hours (Duchin 1982). In 2 studies, patients with chronic kidney failure demonstrated ~2-fold longer half-lives as compared to normal subjects (Giudicelli 1984; Onoyama 1981). Half-life was up to 21 hours in patients with severe kidney impairment and up to 32 hours in patients on chronic hemodialysis in another study (Duchin 1984)

Time to peak: Within 1 to 2 hours

Excretion: Urine (>95%) within 24 hours (40% to 50% as unchanged drug)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Acetab | Apo capto | Capocard | Capoten | Captace | Captophar | Midopril;
  • (AT) Austria: Capace | Captopril genericon pharma | Debax;
  • (AU) Australia: Acenorm | Apo captopril | Capace | Capoten | Captohexal | Captopril bc | Cm captopril | Dbl captopril | Enzace | Sbpa captopril | Topace | Tw captopril | Zedace;
  • (BD) Bangladesh: Acetor | Angiten | Capotril | Capril | Cardopril | Topril;
  • (BE) Belgium: Capoten | Capriltop | Captopril bc | Captopril bexal | Captopril eurogenerics | Captopril merck-generics | Captopril ratiopharm | Captopril sandoz | Captopril teva generics belgium | Captoprimed | Doccaptopri;
  • (BF) Burkina Faso: Captopril denk | Captopril tm;
  • (BG) Bulgaria: Alkadil | Capoten | Tensiomin;
  • (BR) Brazil: Abepoten | Antipressin | Aorten | Aortt | Cabioten | Capobal | Capoten | Capotrat | Capotril | Capotrineo | Capox | Capril | Captil | Captobel | Captocord | Captolab | Captolin | Captomax | Captomed | Captomido | Capton | Captophex | Captopiril | Captopril brasterapica | Captopril laqfa | Captopron | Captosen | Captosif | Captotec | Captozen | Ductopril | Farmanguinhos captopril | Furp captopril | Genoptril | Hipocatril | Hipoten | Hipotensil | Iquego captopril | Labopril | Lafepe captopril | Normapril | Pressomax | Presstopril | Prilpressin | Ritpress | Teusil | Venopril;
  • (CH) Switzerland: Capto-basan | Captopril cophar | Captopril mepha | Captopril upsa | Captosol | Lopirin | Tensobon;
  • (CI) Côte d'Ivoire: Apo capto | Captopril generis | Lopril | Tensoprel;
  • (CL) Chile: Capoten | Properil;
  • (CN) China: Bo tong | Capoten | Pu li bo tong;
  • (CO) Colombia: Altran | Capoten | Captol | Captomed | Captopren | Captopril mk | Cardiopril | Cardopril | Drugsipres | Ecapress | Falaprex | Hipermed | Norpril | Presinorm | Redupres;
  • (CZ) Czech Republic: Alkadil | Apo capto | Capoten | Captopril al | Katopil | Tensiomin;
  • (DE) Germany: Ace hemmer | Ace-hemmer von R.A.N. | Ace-hemmer-ratiopharm | Acenorm | Adocor | Capto | Capto 1a pharma | Capto Corax | Capto dura m | Capto lich | Capto sanorania | Capto-isis | Capto-Puren | Captobeta | Captodoc | Captoflux | Captogamma | Captohexal | Captomerck | Captopress | Captopril 1a pharma | Captopril actavis | Captopril al | Captopril Aristo | Captopril atid | Captopril axsan | Captopril denk | Captopril freemed | Captopril gry | Captopril Pfleger | Captopril sandoz | Captopril Stada | Captopril Temmler | Captopril Verla | Captoreal | Captowieb | Cardiagen | Coronorm | Epicordin | Esparil | Jucapt | Lopirin | Mundil | Phamopril | Sansanal | Sigacap | Tensiomin | Tensobon | Tensostad;
  • (DK) Denmark: Captopril nm;
  • (DO) Dominican Republic: Capoten | Capril | Captoprilan | Captoril | Ecapres | Fratopril | Tensoprel;
  • (EC) Ecuador: Capoten | Captopril Genfar | Captostar | Librapril;
  • (EE) Estonia: Angiopress | Angiopril | Capoten | Captohexal | Captopril AbZ | Captopril cox | Kapteks | Katopil | Nycapril | Tensiomin;
  • (EG) Egypt: Acepril | Angiopress | Capoten | Capotil | Capotril | Farcoprel | Farcopril | Hypopress | Lontensin | Lotensine;
  • (ES) Spain: Alopresin | Capoten | Captopril alter | Captopril Apotex | Captopril apothecon | Captopril bayvit | Captopril bexal | Captopril cinfa | Captopril edigen | Captopril esteve | Captopril mabo | Captopril merck | Captopril mundogen | Captopril normon | Captopril pharmagenus | Captopril ratiopharm | Captopril rubio | Captopril tamarang | Captopril tarbis | Captopril ur | Captosina | Cesplon | Cesplon cor | Dardex | Dilabar | Garanil | Tensoprel;
  • (FI) Finland: Capoten | Captomin | Captopril actavis | Captopril alpharma | Captopril generics | Captopril Merck NM | Captopril pliva | Captopril sandoz | Captostad | Lopril;
  • (FR) France: Captirex | Captolane | Captopril arrow | Captopril Bayer | Captopril biogaran | Captopril g gam | Captopril gnr | Captopril irex | Captopril ivax | Captopril merck | Captopril Qualimed | Captopril ratiopharm | Captopril rpg | Captopril sandoz | Captopril Teva | Captopril Zydus | Lopril | Oltens;
  • (GB) United Kingdom: Acepril d.f | Captomex | Captopril cox | Captopril kent | Captopril sandoz | Ecopace | Hyteneze | Kaplon | Tensopril;
  • (GR) Greece: Capoten | Hypotensor | Neo ipertas | Normolose | Odupril | Pertacilon | Sancap;
  • (HK) Hong Kong: Apo capto | Capoten | Capril | Captopril Stada | Rilcapton | Tensiomin;
  • (HU) Hungary: Capin | Captogamma | Huma-captoril | Tensiomin;
  • (ID) Indonesia: Acendril | Acepress | Capoten | Captensin | Casipril | Dexacap | Farmoten | Forten | Inapril | Locap | Lotensin | Metopril | Otaryl | Otoryl | Praten | Scantensin | Tenofax | Tensicap | Tensobon | Vapril;
  • (IE) Ireland: Aceomel | Actopril | Capoten | Caprill | Captor | Geroten | Tensopril;
  • (IL) Israel: Aceril | Apocapen | Capti;
  • (IN) India: Aceten | Alcoryl | Capotril;
  • (IQ) Iraq: Caporil | Captoneer | Captopril 25 kindi | Captopril 50 kindi | Captopril awa | Captopril mdi | Captosaf;
  • (IT) Italy: Acepress | Aceprilex | Capoten | Captopril actavis | Captopril doc | Captopril drm | Captopril eg | Maxipril | Tenpril;
  • (JO) Jordan: Capocard | Capoten | Midopril | Miniten;
  • (JP) Japan: Apopril | Brealin | Capotec | Captopril hexal | Captoril bristol-myers | Captoril sankyo | Captoruna | Captowa | Corocalum | Dowpril | Kapuseal | Katonaplon | Kokapto | Ktplon | Mercapril | Onfrule;
  • (KE) Kenya: Acetan | Angiopril | Captocos | Captolab | Captopril denk | Cardopril | Ropril;
  • (KR) Korea, Republic of: Adolpan | Capoten | Capril | Captifen | Captil | Captogen | Captonal | Captopril ID | Cutoril | Ketanine | Ketonil | Mecaflil | Samjin captopril | Topril;
  • (KW) Kuwait: Acetab | Capocard | Capoten | Miniten;
  • (LB) Lebanon: Adocor | Apo capoten | Apo captopril | Capoten | Captace | Captopril Genericon | Orbace | Rivtopril | Tensiopril;
  • (LT) Lithuania: Alkadil | Angiopress | Angiopril | Apo capto | Capoten | Capril | Captohexal | Captopril AbZ | Captopril ac | Captopril arena | Captopril bp | Kaptex | Katopil | Novo captopril | Ropril | Tensiomin;
  • (LU) Luxembourg: Capoten | Captohexal | Captopril Mylan | Doccaptopri;
  • (LV) Latvia: Alkadil | Angiopress | Angiopril | Capoten | Capril | Captogamma | Captohexal | Captopril gry | Kaptex | Katopil | Novo captopril | Tensiomin;
  • (MA) Morocco: Capen | Convertal | Hipotensil | Lopril;
  • (MX) Mexico: Altiver | Atrisol | Biodezil | Bioxil | Brucap | Bucamex | Bugazon | Capotena | Capriwen | Captopril darier | Captopril GI | Captopril gi diba | Captopril gi kendr | Captopril gi pharm | Captopril gi serra | Captopril protein | Captopril raam | Captopril silanes | Captopril wandel | Captoser | Captral | Cardipril | Catona | Condabif | Ecapresan | Ecapril | Ecaten | Enlace | Genopril | Hipertex | Ipyrol | Katodem | Kenolan | Keyerpril | Lenpryl | Midrat | Miocap | Neulastrol | Novapres | Ormoten | Ospil | Proldin | Reductel | Reduprec | Rilten | Sabtres | Tenca i | Tensil | Toprilem | Tropisol | Varaxil | Viegnur;
  • (MY) Malaysia: Apo capto | Apuzin | Capoten | Capriten | Captohexal | Epsitron | Kimafan | Taguar;
  • (NG) Nigeria: C pril | Donypril | N & n captopril | Taguar;
  • (NL) Netherlands: Capoten | Captopril Accord | Captopril actavis | Captopril katwijk | Captopril ratiopharm | Captoril katwijk;
  • (NO) Norway: Capoten | Captopril AbZ | Captopril Mylan | Captopril viatris;
  • (NZ) New Zealand: Apo captopril | Capoten | Captohexal | M captopril;
  • (PE) Peru: Caposan | Capoten | Capressior | Captomed | Melatil | Nolectin | Presicaptil;
  • (PH) Philippines: Ace-bloc | Biopril | Bloc Med | Capomed | Capotec | Capoten | Captace | Captobes | Captogen | Captor | Captril | Conamid | Hartylox | Hyperstop | Normil | Primace | Retensin | Ritemed Captopril | Spec Ace | Tensoril | Tgp capto | Typrilace | Unihype | Vasostad;
  • (PK) Pakistan: Acetopril | Aptil | Bentoril | Capace | Capoten | Capril | Captace | Captil | Capto | Catoper | G-cap | Garan | Katopil | Maripril | Nobeten | Plumax | Qutril | Ropril | Tensiomin | Vasokap | Vasotone | Vegaten;
  • (PL) Poland: Capoten | Captopril jelfa | Tensiomin | Tensobon;
  • (PR) Puerto Rico: Capoten;
  • (PT) Portugal: Calpix | Capoten | Capritin | Captopril merck-generics | Carencil | Convertal | Hipotensil | Pressil | Prilovase | Tensopril | Vidapril;
  • (QA) Qatar: Acetab | Apo-Capto | Capocard | Farcopril | Hypopress | Lotensine;
  • (RO) Romania: Alkadil | Capocard | Capoten | Captopril arena | Captopril eel | Captopril laropharm | Captopril lph | Farcopril | Hypotensor | Kapril;
  • (RU) Russian Federation: Aceten | Acetor | Alkadil | Angiopril | Apo capto | Blocordil | Capocard | Capopharm | Capoten | Capto | Captopril akos | Captopril akri | Captopril biosynt | Captopril egis | Captopril fpo | Captopril n.s. | Captopril of | Captopril sandoz | Captopril sar | Captopril stad int | Captopril sti | Captopril Teva | Captopril ubf | Captopril velpharm | Gen captopril | Kapoten | Katopil | Kmp captopril | Novo captopril | Rilcapton | Tensiomin | Vero captopril;
  • (SA) Saudi Arabia: Acetab | Apo captopril | Capocard | Capoten | Captophar | Miniten | Novo captoril;
  • (SE) Sweden: Captopril actavis | Captopril Mylan | Captopril ratiopharm;
  • (SG) Singapore: Apo capto | Capoten | Catoplin | Dexacap | Ketanine | Pertacilon | Rilcapton;
  • (SI) Slovenia: Alkadil | Kaptopril;
  • (SK) Slovakia: Alkadil | Capoten | Katopil | Tensiomin;
  • (SR) Suriname: Apo capto | Capace | Captopril Accord | Captopril apothecon | Captopril denk | Captopril mk | Captopril Mylan | Captopril sandoz | Epsitron;
  • (TH) Thailand: Capoten | Capril | Epsitron | Gemzil | Tensiomin;
  • (TN) Tunisia: Actopril | Capocard | Capril | Capto Pril Alliance | Captolane | Convertal | Lopril | Tensopril;
  • (TR) Turkey: Kapril | Kaptoril;
  • (TW) Taiwan: Aceloc | Acepril | Aceprotin | Apo capto | Apuzin | Asisten | C.p.t | Cabudan | Calatec | Capdon | Capomil | Caponal | Capoten | Capotil | Capril | Caproine | Captolin | Captolong | Captopin | Captopri | Captrol | Catopren | Ceporin | Hyperten | Kecap | Meriga | Rilcapton | Smarten | Suyea | Tecapril | Vasodil;
  • (UA) Ukraine: Aceten | Capoten | Capotril | Hypotensor | Katopil | Tensiomin;
  • (UG) Uganda: Angiopril | Captoglo | Captopril denk | Epsitron;
  • (UY) Uruguay: Asisten | Capoten | Captopril Pellier | Captopril teuto | Cercor | Isopril | Yaraten;
  • (VE) Venezuela, Bolivarian Republic of: Capoten | Capox | Captopril Penta | Captoril | Captoz | Ceplon | Lidinox | Presinorm | Prileno | Tabulan;
  • (VN) Viet Nam: Bidipril | Captagim | Mildocap;
  • (ZA) South Africa: Aceten | Adco-captopril | Apo captopril | Bio Captopril | Capace | Capoten | Captohexal | Captomax | Cardiace | Merck-captopril | Rolab-captopril;
  • (ZM) Zambia: Capril | Kamtopril;
  • (ZW) Zimbabwe: Angiopril | Caipolex
  1. Adelborg K, Nicolaisen SK, Hasvold P, Palaka E, Pedersen L, Thomsen RW. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - a population-based cohort study. PLoS One. 2019;14(6):e0218739. doi:10.1371/journal.pone.0218739 [PubMed 31226134]
  2. Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension. 2001;37(6):1440-1443. doi:10.1161/01.hyp.37.6.1440 [PubMed 11408392]
  3. Alharbi FF, Kholod AAV, Souverein PC, et al. The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase. Fundam Clin Pharmacol. 2017;31(6):676-684. doi:10.1111/fcp.12313 [PubMed 28767167]
  4. Alkurtass DA, Al-Jazairi AS. Possible captopril-induced toxic epidermal necrolysis. Ann Pharmacother. 2003;37(3):380-383. doi:10.1345/aph.1C284 [PubMed 12639167]
  5. Allen LV Jr and Erickson MA 3rd, Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996;53(18):2179-2184. [PubMed 8879325]
  6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. [PubMed 12479763]
  7. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. Obstet Gynecol. 2019;133(1):e26-e50. [PubMed 30575676]
  8. American Diabetes Association (ADA). Standards of medical care in diabetes–2021. Diabetes Care. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.
  9. Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA Task Force Members; Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):2354-94. doi:10.1161/CIR.0000000000000133 [PubMed 25249586]
  10. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. [PubMed 27060684]
  11. Angeli P, Chiesa M, Caregaro L, et al. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. Arch Intern Med. 1991;151(4):678-682. [PubMed 2012448]
  12. Ammar H, Chaabane A, Ben Fadhel N, Chadli Z, Ben Fredj N, Aouam K. Drug rash with eosinophilia and systemic symptoms: Captropril, an unusual culprit drug. Dermatitis. 2019;30(3):238-239. doi:10.1097/DER.0000000000000464 [PubMed 31045940]
  13. Antman EM, Anbe SC, Alpert JS, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110(5):588-636. [PubMed 15289388]
  14. Apo-Capto (captopril) [product monograph]. Weston, Ontario, Canada: Apotex Inc; November 2013.
  15. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007, p. 28.
  16. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123(21):2434-2506. [PubMed 21518977]
  17. Artman M, Graham TP Jr. Guidelines for vasodilator therapy of congestive heart failure in infants and children. Am Heart J. 1987;113(4):994-1005. [PubMed 3031972]
  18. ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.
  19. Bailey RR. Captopril-induced membranous nephropathy. N Z Med J. 1992;105(926):22. [PubMed 1549277]
  20. Baker-Smith CM, Benjamin DK Jr, Califf RM, et al. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. Clin Pharmacol Ther. 2010;87(6):668-671. [PubMed 20130570]
  21. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685-693. [PubMed 10724055]
  22. Banerji A, Blumenthal KG, Lai KH, Zhou L. Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record. J Allergy Clin Immunol Pract. 2017;5(3):744-749. doi:10.1016/j.jaip.2017.02.018 [PubMed 28377081]
  23. Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. Drug Saf. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2 [PubMed 31020549]
  24. Ben Salem C, Chenguel L, Ghariani N, Denguezli M, Hmouda H, Bouraoui K. Captopril-induced lichen planus pemphigoides. Pharmacoepidemiol Drug Saf. 2008;17(7):722-724. doi:10.1002/pds.1618 [PubMed 18489011]
  25. Bezalel S, Mahlab-Guri K, Asher I, Werner B, Sthoeger ZM. Angiotensin-converting enzyme inhibitor-induced angioedema. Am J Med. 2015;128(2):120-125. doi:10.1016/j.amjmed.2014.07.011 [PubMed 25058867]
  26. Bhatt MD, Thomas JE, Mondal TK. Variation in captopril formulations in pharmacies across Canada. Paediatr Child Health. 2011;16(4):e30-e32. [PubMed 22468132]
  27. Bianchi S, Aucella F, De Nicola L, Genovesi S, Paoletti E, Regolisti G. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. J Nephrol. 2019;32(4):499-516. doi:10.1007/s40620-019-00617-y [PubMed 31119681]
  28. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. doi:10.1002/hep.31884 [PubMed 33942342]
  29. Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. BMC Med. 2013;11:141. doi:10.1186/1741-7015-11-141 [PubMed 23721258]
  30. Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). Allergo J Int. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6 [PubMed 26120552]
  31. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54(3):516-523. doi:10.1161/HYPERTENSIONAHA.109.134197 [PubMed 19581505]
  32. Brown T, Gonzalez J, Monteleone C. Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature. J Clin Hypertens (Greenwich). 2017;19(12):1377-1382. doi:10.1111/jch.13097 [PubMed 28994183]
  33. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60(1):8-13. doi:10.1016/S0009-9236(96)90161-7 [PubMed 8689816]
  34. Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. JAMA. 1997;278(3):232-233. doi:10.1001/jama.278.3.232 [PubMed 9218671]
  35. Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension. 2008;51(1):141-147. doi:10.1161/HYPERTENSIONAHA.107.096552 [PubMed 18025295]
  36. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2013;35(suppl 1):1-212.
  37. Capoten (captopril) [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies Inc; August 2017.
  38. Captopril tablets [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; November 2019.
  39. Captopril tablets [prescribing information]. Melville, NY: Amici Pharmaceuticals LLC; June 2019.
  40. Castro del Castillo A, Rodriguez M, Gonzalez E, Rodriguez F, Estruch J. Dose-response effect of sublingual captopril in hypertensive crises. J Clin Pharmacol. 1988;28(7):667-670. [PubMed 3063729]
  41. Cattran DC, Appel GB, Coppo R. IgA nephropathy: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 13, 2023.
  42. Ceyhan B, Karaaslan Y, Caymaz O, et al. Comparison of sublingual captopril and sublingual nifedipine in hypertensive emergencies. Japan J Pharmacol. 1990;52(2):189-193. [PubMed 2179605]
  43. Chaabane A, Fadhl NB, Chadly Z, Fredj NB, Boughattas NA, Aouam K. Captopril-induced DRESS: first reported case confirmed by patch test. Dermatitis. 2013;24(5):255-257. doi:10.1097/DER.0b013e3182a5d86d [PubMed 24030372]
  44. Chase MP, Fiarman GS, Scholz FJ, et al. Angioedema of the small bowel due to an angiotensin-converting enzyme inhibitor. J Clin Gastroenterol. 2000;31(3):254-257. [PubMed 11034011]
  45. Chisi JE, Wdzieczak-Bakala J, Thierry J, Briscoe CV, Riches AC. Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures. Stem Cells. 1999;17(6):339-344. doi:10.1002/stem.170339 [PubMed 10606162]
  46. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289(19):2560-2572. [PubMed 12748199]
  47. Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082 [PubMed 31841131]
  48. Collins DA, Patel S, Eastwood JB, Bourke BE. Favourable outcome of scleroderma renal crisis. J R Soc Med. 1996;89(1):49P-50P. [PubMed 8709086]
  49. Conlin P, Moore T, Swartz S, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension. 2000;36(3):461-465. [PubMed 10988282]
  50. Cooper RA. Captopril-associated neutropenia. Who is at risk? Arch Intern Med. 1983;143(4):659-660. [PubMed 6340620]
  51. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443-2451. [PubMed 16760444]
  52. Crantock L, Prentice R, Powell L. Cholestatic jaundice associated with captopril therapy. J Gastroenterol Hepatol. 1991;6(5):528-530. doi:10.1111/j.1440-1746.1991.tb00899.x [PubMed 1932674]
  53. Damasceno A, Ferreira B, Patel S, Sevene E, Polónia J. Efficacy of captopril and nifedipine in black and white patients with hypertensive crisis. J Hum Hypertens. 1997;11(8):471-476. [PubMed 9322826]
  54. Daskalopoulos G, Pinzani M, Murray N, Hirschberg R, Zipser RD. Effects of captopril on renal function in patients with cirrhosis and ascites. J Hepatol. 1987;4(3):330-336. doi:10.1016/s0168-8278(87)80542-1 [PubMed 3298415]
  55. Devlin RG, Fleiss PM. Captopril in human blood and breast milk. J Clin Pharmacol. 1981;21(2):110-113. [PubMed 7014657]
  56. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 suppl):169S-173S. doi:10.1378/chest.129.1_suppl.169S [PubMed 16428706]
  57. Doane J, Stults B. Visual hallucinations related to angiotensin-converting enzyme inhibitor use: case reports and review. J Clin Hypertens (Greenwich). 2013;15(4):230-233. [PubMed 23551721]
  58. Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. Cloherty and Stark's Manual of Neonatal Care. 8th ed. Lippincott Williams & Wilkins; 2017.
  59. Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ. Elimination kinetics of captopril in patients with renal failure. Kid Internat. 1984;25(6):942-947. doi:10.1038/ki.1984.114 [PubMed 6381858]
  60. Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN. Captopril kinetics. Clin Pharmacol Ther. 1982;31(4):452-458. [PubMed 7037265]
  61. Duerr M, Glander P, Diekmann F, Dragun D, Neumayer HH, Budde K. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol. 2010;5(4):703-708. doi:10.2215/CJN.07371009 [PubMed 20093343]
  62. Edwards CR, Drury P, Penketh A, Damluji SA. Successful reintroduction of captopril following neutropenia. Lancet. 1981;1(8222):723. doi:10.1016/s0140-6736(81)91998-x [PubMed 6110936]
  63. el-Makri A, Larabi MS, Kechrid C, Belkahia C, Ben Ayed H. Fatal bone-marrow suppression associated with captopril. Br Med J (Clin Res Ed). 1981;283(6286):277-278. doi:10.1136/bmj.283.6286.277-a [PubMed 6788292]
  64. Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCPS, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.
  65. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  66. Fakhouri F, Schwotzer N, Cabiddu G, et al. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. Kidney Int. 2022:S0085-2538(22)01015-8. doi:10.1016/j.kint.2022.10.029 [PubMed 36481180]
  67. Flynn JT. The hypertensive neonate. Semin Fetal Neonatal Med. 2020;25(5):101138. doi:10.1016/j.siny.2020.101138 [PubMed 33223015]
  68. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3);e20171904. doi:10.1542/peds.2017-1904 [PubMed 28827377]
  69. Fox KM; EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (The EUROPA Study). Lancet. 2003;362(9386):782-788. [PubMed 13678872]
  70. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med. 2000;160(17):2645-2650. doi:10.1001/archinte.160.17.2645 [PubMed 10999979]
  71. Friedman WF, George BL. Treatment of congestive heart failure by altering loading conditions of the heart. J Pediatr. 1985;106(5):697-706. [PubMed 3923176]
  72. Friedman IS, Rudikoff D, Phelps RG, Sapadin AN. Captopril-triggered linear IgA bullous dermatosis. Int J Dermatol. 1998;37(8):608-612. doi:10.1046/j.1365-4362.1998.00544.x [PubMed 9732010]
  73. Fujimura A, Kajiyama H, Ebihara A, Iwashita K, Nomura Y, Kawahara Y. Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis. Nephron. 1986;44(4):324-328. doi:10.1159/000184014 [PubMed 3025754]
  74. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061 [PubMed 26934393]
  75. Gantenbein MH, Bauersfeld U, Baenziger O, et al. Side effects of angiotensin converting enzyme inhibitor (captopril) in newborns and young infants. J Perinat Med. 2008;36(5):448-452. [PubMed 18605972]
  76. Gardner NJ. Treating hypertension in Black patients. JAAPA. 2022;35(2):15-18. doi:10.1097/01.JAA.0000791512.37549.64 [PubMed 35076435]
  77. Gentilini P, Romanelli RG, La Villa G, et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology. 1993;104(2):588-594. doi:10.1016/0016-5085(93)90431-b [PubMed 8425702]
  78. Ghaedi F, Etesami I, Aryanian Z, et al. Drug-induced pemphigus: A systematic review of 170 patients. Int Immunopharmacol. 2021;92:107299. doi:10.1016/j.intimp.2020.107299 [PubMed 33418246]
  79. Giudicelli JF, Chaignon M, Richer C, Giroux B, Guedon J. Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients. Br J Clin Pharmac. 1984;18(5):749-758. [PubMed 6095887]
  80. Gleason MM, Roloff JS, Cyran SE, Weber HS, Baylen BG, Myers JL. Captopril-induced bone marrow suppression in two cardiac patients with trisomy 21. Pediatr Cardiol. 1993;14(4):227-229. doi:10.1007/BF00795376 [PubMed 8255797]
  81. Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63(4):878-885. doi: 10.1161/HYP.0000000000000003. [PubMed 24243703]
  82. Gorsane I, Ayed TB, Aoudia R, et al. Simultaneous acute pancreatitis and angioedema associated with angiotensin-converting enzyme inhibitor. Saudi J Kidney Dis Transpl. 2019;30(6):1479-1484. doi:10.4103/1319-2442.275498 [PubMed 31929301]
  83. Groel JT, Tadros SS, Dreslinski GR, Jenkins AC. Long-term antihypertensive therapy with captopril. Hypertension. 1983;5(5 pt 2):III145-151. doi:10.1161/01.hyp.5.5_pt_2.iii145 [PubMed 6354930]
  84. Grossman E, Morag B, Nussinovitch N, et al. Clinical use of captopril in Takayasu's disease. Arch Intern Med. 1984;144(1):95-96. [PubMed 6140907]
  85. Hallberg P, Persson M, Axelsson T, et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population. Pharmacogenomics. 2017;18(3):201-213. doi:10.2217/pgs-2016-0184 [PubMed 28084903]
  86. Hashmi HR, Jabbour R, Schreiber Z, Khaja M. Benazepril-induced agranulocytosis: A case report and review of the literature. Am J Case Rep. 2016;17:425-428. doi:10.12659/ajcr.898028 [PubMed 27335175]
  87. Havelka J, Boerlin HJ, Studer A, et al. Long-term experience with captopril in severe hypertension. Br J Clin Pharmacol. 1982;14 suppl 2(suppl 2):71S-76S. doi:10.1111/j.1365-2125.1982.tb02060.x [PubMed 6753907]
  88. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 [PubMed 35363499]
  89. Helmer A, Slater N, Smithgall S. A review of ACE inhibitors and ARBs in black patients with hypertension. Ann Pharmacother. 2018;52(11):1143-1151. doi:10.1177/1060028018779082 [PubMed 29808707]
  90. Henriksen JH, Moller S. Liver cirrhosis and arterial hypertension. World J Gastroenterol. 2006;12(5):678-685. doi:10.3748/wjg.v12.i5.678 [PubMed 16521178]
  91. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(23):2610-2642. [PubMed 22064600]
  92. Hofmann GA, Weber B. Drug-induced photosensitivity: culprit drugs, potential mechanisms and clinical consequences. J Dtsch Dermatol Ges. 2021;19(1):19-29. doi:10.1111/ddg.14314 [PubMed 33491908]
  93. Holt HK, Gildengorin G, Karliner L, Fontil V, Pramanik R, Potter MB. Differences in hypertension medication prescribing for Black Americans and their association with hypertension outcomes. J Am Board Fam Med. 2022;35(1):26-34. doi:10.3122/jabfm.2022.01.210276 [PubMed 35039409]
  94. Hurault de Ligny BH, Ryckelynck JP, Mintz P, Levy G, Muller G. Captopril therapy in preeclampsia. Nephron. 1987;46(3):329-330. [PubMed 3306419]
  95. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234-242. doi:10.7326/0003-4819-117-3-234 [PubMed 1616218]
  96. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. [PubMed 10891521]
  97. Jaffe IA. Adverse effects profile of sulfhydryl compounds in man. Am J Med. 1986;80(3):471-476. doi:10.1016/0002-9343(86)90722-9 [PubMed 2937293]
  98. Jamerson KA, Basile J. Prompt, aggressive BP lowering in high-risk patients. J Clin Hypertens (Greenwich). 2008;10(1 suppl 1):S40-S48. doi:10.1111/j.1524-6175.2007.08145.x [PubMed 18174783]
  99. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. doi:10.1001/jama.2013.284427 [PubMed 24352797]
  100. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199-e267. doi:10.1161/CIR.0000000000000041 [PubMed 24682347]
  101. Kammerl MC, Schaefer RM, Schweda F, Schreiber M, Riegger GA, Krämer BK. Extracorporal therapy with AN69 membranes in combination with ACE inhibition causing severe anaphylactoid reactions: still a current problem? Clin Nephrol. 2000;53(6):486-488. [PubMed 10879671]
  102. Karakilic E, Buyukcam F, Kocalar G, Gedik S, Atalar E. Same effect of sublingual and oral captopril in hypertensive crisis. Eur Rev Med Pharmacol Sci. 2012;16(12):1642-1645. [PubMed 23161035]
  103. Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in Stroke. 2015;46(2):e54]. Stroke. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024. [PubMed 24788967]
  104. Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Inter Suppl. 2012;2(5):v-405.
  105. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019 [PubMed 32998798]
  106. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(suppl 5):S1-S127. doi:10.1016/j.kint.2022.06.008 [PubMed 36272764]
  107. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021b;99 (3S):S1-S87. doi:10.1016/j.kint.2020.11.003 [PubMed 33637192]
  108. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Chapter 10: immunoglobulin A nephropathy. Kidney Int Suppl (2011). 2012;2(2):209-217. doi:10.1038/kisup.2012.23 [PubMed 25018935]
  109. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney Inter Suppl. 2013;3:1-150.
  110. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021a;100(suppl 4):S1-S276. doi:10.1016/j.kint.2021.05.021 [PubMed 34556256]
  111. Kocab MA, Coppola D, Hiotis S, Karl RC, Barthel JS. Captopril-associated cholestasis complicating the management of pancreatic cancer. Surg Endosc. 2000;14(7):681. doi:10.1007/s004640020082 [PubMed 11265073]
  112. Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165(14):1637-1642. doi:10.1001/archinte.165.14.1637 [PubMed 16043683]
  113. Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE inhibitor-induced angioedema: a review. Curr Hypertens Rep. 2018;20(7):55. doi:10.1007/s11906-018-0859-x [PubMed 29884969]
  114. Kramer BL, Massie BM, Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation. 1983;67(4):807-816. doi:10.1161/01.cir.67.4.807 [PubMed 6337741]
  115. Kubo SH, Cody RJ. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. Clin Pharmacokin. 1985;10(5):377-391. [PubMed 2994938]
  116. Kuechle MK, Stegemeir E, Maynard B, Gibson LE, Leiferman KM, Peters MS. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol. 1994;30(2 Pt 1):187-192. doi:10.1016/s0190-9622(94)70015-x [PubMed 7904616]
  117. Kumari R, Timshina DK, Thappa DM. Drug hypersensitivity syndrome. Indian J Dermatol Venereol Leprol. 2011;77(1):7-15. doi:10.4103/0378-6323.74964 [PubMed 21220873]
  118. Lee GJ, Cohen R, Chang AC, Cleary JP. Angiotensin converting enzyme inhibitor (ACEI)-induced acute renal failure in premature newborns with congenital heart disease. J Pediatr Pharmacol Ther. 2010;15(4):290-296. [PubMed 22477817]
  119. Levy M, Koren G, Klein J, et al. Captopril pharmacokinetics, blood pressure response and plasma renin activity in normotensive children with renal scarring. Dev Pharmacol Ther. 1991;16(4):185-193.
  120. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [published correction appears in N Engl J Med. 1993;330(2):152]. N Engl J Med. 1993;329(20):1456-1462. [PubMed 8413456]
  121. Lindle KA, Dinh K, Moffett BS, et al. Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease. Pediatr Cardiol. 2014;35(3):499-506. [PubMed 24233240]
  122. Lluch-Bernal M, Novalbos A, Umpierrez A, Figueredo E, Bombin C, Sastre J. Cutaneous reaction to captopril with positive patch test and lack of cross-sensitivity to enalapril and benazepril. Contact Dermatitis. 1998;39(6):316-367. doi:10.1111/j.1600-0536.1998.tb05952.x [PubMed 9874028]
  123. Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. J Obstet Gynaecol Can. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002 [PubMed 35577426]
  124. Mann JFE. Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 9, 2021b.
  125. Mann JFE, Flack JM. Hypertension in adults: Initial drug therapy. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 7, 2023.
  126. Markusse HM, Meyboom RH. Gynaecomastia associated with captopril. Br Med J (Clin Res Ed). 1988;296(6631):1262-1263. doi:10.1136/bmj.296.6631.1262-c [PubMed 3133043]
  127. Maroteau C, Siddiqui MK, Veluchamy A, et al; PREDICTION-ADR. Exome sequencing reveals common and rare variants in F5 associated with ACE inhibitor and angiotensin receptor blocker-induced angioedema. Clin Pharmacol Ther. 2020;108(6):1195-1202. doi:10.1002/cpt.1927 [PubMed 32496628]
  128. Martínez JC, Fuentes MJ, Armentia A, Vega JM, Fernández A. Dermatitis to captopril. Allergol Immunopathol (Madr). 2001;29(6):279-280. doi:10.1016/s0301-0546(01)79071-4 [PubMed 11834188]
  129. Mastrobattista JM. Angiotensin converting enzyme inhibitors in pregnancy. Semin Perinatol. 1997;21(2):124-134. doi: 10.1016/s0146-0005(97)80055-9. [PubMed 9201818]
  130. Meyer TE. Primary pharmacologic therapy of heart failure with reduced ejection fraction in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 2, 2021.
  131. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51(6):1624-1630. doi:10.1161/HYPERTENSIONAHA.108.110270. [PubMed 18413488]
  132. Mimran A, Insua A, Ribstein J, Bringer J, Monnier L. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care. 1988;11(10):850-853. doi:10.2337/diacare.11.10.850 [PubMed 3073076]
  133. Mirkin BL, Newman TJ. Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics. 1985;75(6):1091-1100. [PubMed 3889818]
  134. Momma K. ACE inhibitors in pediatric patients with heart failure. Paediatr Drugs. 2006;8(1):55-69. [PubMed 16494512]
  135. Montinaro V, Cicardi M. ACE inhibitor-mediated angioedema. Int Immunopharmacol. 2020;78:106081. doi:10.1016/j.intimp.2019.106081 [PubMed 31835086]
  136. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10(4):499-509. doi:10.1111/j.1365-2753.2003.00484.x [PubMed 15482412]
  137. Moussa Z, Schiano T, Spatoliatore G, Salman S. Neutropenia induced by low-dose captopril. N Y State J Med. 1992;92(5):219-220. [PubMed 1614676]
  138. Mu G, Xiang Q, Zhou S, et al. Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis. Pharmacogenomics. 2019;20(3):189-212. doi:10.2217/pgs-2018-0157 [PubMed 30672376]
  139. Mu G, Xiang Q, Zhang Z, et al. PNPT1 and PCGF3 variants associated with angiotensin-converting enzyme inhibitor-induced cough: a nested case-control genome-wide study. Pharmacogenomics. 2020;21(9):601-614. doi:10.2217/pgs-2019-0167 [PubMed 32397904]
  140. Mulla H, Tofeig M, Bu'Lock F, et al. Variations in captopril formulations used to treat children with heart failure: a survey in the United Kingdom. Arch Dis Child. 2007;92(5):409-411. [PubMed 17363396]
  141. Nanba K, Tamanaha T, Nakao K, et al. Confirmatory testing in primary aldosteronism. J Clin Endocrinol Metab. 2012;97(5):1688-1694. doi: 10.1210/jc.2011-2504. [PubMed 22419718]
  142. National Heart, Lung, and Blood Institute, National Institutes of Health. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Clinical Practice Guidelines, 2012. http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf
  143. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 suppl 4th report):555-576. [PubMed 15286277]
  144. National Institute for Health and Care Excellence. Drug allergy: Diagnosis and management. Clinical guideline 183. September 2014. www.nice.org.uk/guidance/cg183
  145. National Institute for Health and Care Excellence (NICE). NICE guideline hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.
  146. Noyada (captopril) [product monograph]. Montreal, Quebec, Canada: Ethypharm Inc; December 2023.
  147. O'Dea RF, Mirkin BL, Alward CT, Sinaiko AR. Treatment of neonatal hypertension with captopril. J Pediatr. 1988;113(2):403-406. [PubMed 3294363]
  148. O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362-e425. doi:10.1161/CIR.0b013e3182742cf6 [PubMed 23247304]
  149. Oktaviono YH, Kusumawardhani N. Hyperkalemia associated with angiotensin converting enzyme inhibitor or angiotensin receptor blockers in chronic kidney disease. Acta Med Indones. 2020;52(1):74-79. [PubMed 32291375]
  150. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239-e1311. doi:10.1161/CIR.0000000000001250 [PubMed 38718139]
  151. Onoyama K, Hirakata H, Iseki K, et al. Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure. Hypertension. 1981;3(4):456-459. [PubMed 7030952]
  152. Os I, Bratland B, Dahlöf B, Gisholt K, Syvertsen JO, Tretli S. Female preponderance for lisinopril-induced cough in hypertension. Am J Hypertens. 1994;7(11):1012-1015. doi:10.1093/ajh/7.11.1012 [PubMed 7848615]
  153. Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf. 1996;15(1):72-78. doi:10.2165/00002018-199615010-00006 [PubMed 8862965]
  154. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100(23):2312-2318. [PubMed 10587334]
  155. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585-592. doi:10.1056/NEJMra035279 [PubMed 15295051]
  156. Pariente EA, Bataille C, Bercoff E, Lebrec D. Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology. 1985;88(5 pt 1):1255-1259. doi:10.1016/s0016-5085(85)80088-3 [PubMed 3884428]
  157. Park MK, Salamat M. Appendix E: Drugs used in pediatric cardiology. In: Park's Pediatric Cardiology for Practitioners. 7th ed. Elsevier Health Sciences; 2021: 477-492.
  158. Peces R. Anaphylactoid reaction induced by ACEI during haemodialysis with a surface-treated AN69 membrane. Nephrol Dial Transplant. 2002;17(10):1859-1860. doi:10.1093/ndt/17.10.1859 [PubMed 12271008]
  159. Pereira CM, Tam YK, Collins-Nakai RL. The pharmacokinetics of captopril in infants with congestive heart failure. Ther Drug Monit. 1991;13(3):209-214.
  160. Perkovic V. Treatment of diabetic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 2, 2023.
  161. Perlman JM, Volpe JJ. Neurologic complications of captopril treatment of neonatal hypertension. Pediatrics. 1989;83(1):47-52. [PubMed 2642619]
  162. Pfeffer MA, Greaves SC, Arnold JM, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The Healing and Early Afterload Reducing Therapy Trial. Circulation. 1997;95(12):2643-2651. [PubMed 9193433]
  163. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-1906. [PubMed 14610160]
  164. Phillips WG, Vaughan-Jones S, Jenkins R, Breathnach SM. Captopril-induced lichenoid eruption. Clin Exp Dermatol. 1994;19(4):317-320. doi:10.1111/j.1365-2230.1994.tb01203.x [PubMed 7955473]
  165. Prieto-García L, Pericacho M, Sancho-Martínez SM, et al. Mechanisms of triple whammy acute kidney injury. Pharmacol Ther. 2016;167:132-145. doi:10.1016/j.pharmthera.2016.07.011 [PubMed 27490717]
  166. Quan A . Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev. 2006;82(1):23-28. [PubMed 16427219]
  167. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012;30(3):e156-e166. doi:10.1111/j.1755-5922.2010.00258.x [PubMed 21883995]
  168. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158(1):26-32. doi:10.1001/archinte.158.1.26 [PubMed 9437375]
  169. Refer to manufacturer's labeling.
  170. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241. [PubMed 30165544]
  171. Rosenbaum AJ, Luciano JA, Marburger R, Hume E. Acute kidney injury in the setting of knee arthroplasty: a case report and discussion investigating Angiotensin-converting enzyme inhibitors as the culprit. HSS J. 2011;7(2):183-186. doi:10.1007/s11420-010-9189-5 [PubMed 22754420]
  172. Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Soc Hypertens. 2015;9(6):453-498. doi: 10.1016/j.jash.2015.03.002. [PubMed 25840695]
  173. Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651-1653. doi:10.1002/hep.26359. [PubMed 23463403]
  174. Sato A, Fukuda S. A prospective study of frequency and characteristics of cough during ACE inhibitor treatment. Clin Exp Hypertens. 2015;37(7):563-568. doi:10.3109/10641963.2015.1026040 [PubMed 25992489]
  175. Scammell AM, Arnold R, Wilkinson JL. Captopril in treatment of infant heart failure: a preliminary report. Int J Cardiol. 1987;16(3):295-301. [PubMed 3308715]
  176. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS; Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104(16):1985-1991. doi:10.1161/hc4101.096153 [PubMed 11602506]
  177. Scott J, Jones T, Redaniel MT, May MT, Ben-Shlomo Y, Caskey F. Estimating the risk of acute kidney injury associated with use of diuretics and renin angiotensin aldosterone system inhibitors: A population based cohort study using the clinical practice research datalink. BMC Nephrol. 2019;20(1):481. doi:10.1186/s12882-019-1633-2 [PubMed 31888533]
  178. Shaw NJ, Wilson N, Dickinson DF. Captopril in heart failure secondary to a left to right shunt. Arch Dis Child. 1988;63(4):360-363. [PubMed 3284479]
  179. Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA. 1988;260(7):967-970. [PubMed 2840522]
  180. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458-4573. [PubMed 22052934]
  181. Smoger SH, Sayed MA. Simultaneous mucosal and small bowel angioedema due to captopril. South Med J. 1998;91(11):1060-1063. [PubMed 9824192]
  182. Solinger AM. Exfoliative dermatitis from captopril. Cutis. 1982;29(5):473-474. [PubMed 6212200]
  183. Starr MC, Flynn JT. Neonatal hypertension: cases, causes, and clinical approach. Pediatr Nephrol. 2019;34(5):787-799. doi:10.1007/s00467-018-3977-4 [PubMed 29808264]
  184. Suarez M, Ho PW, Johnson ES, Perez G. Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy. Am J Med. 1986;81(2):336-338. doi:10.1016/0002-9343(86)90274-3 [PubMed 3526889]
  185. Taguma Y, Kitamoto Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985;313(26):1617-1620. doi:10.1056/NEJM198512263132601 [PubMed 3906398]
  186. Tarcan A, Gürakan B, Ozbek N. Captopril-induced pancytopenia in a premature newborn. J Paediatr Child Health. 2004;40(7):404-405. doi:10.1111/j.1440-1754.2004.00412.x [PubMed 15228574]
  187. Teva-Captopril (captopril) tablets, USP [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; February 2021.
  188. Thompson A, Fleischmann KE, Smilowitz NR, et al. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;150(19):e351-e442. doi:10.1161/CIR.0000000000001285 [PubMed 39316661]
  189. Trimble MA, Sketch MH Jr, Mehta RH. Hemolytic anemia: a rare but potentially serious adverse effect of captopril. Herz. 2007;32(1):62-64. doi:10.1007/s00059-007-2956-5 [PubMed 17323037]
  190. Tschollar W, Belz GG. Sublingual captopril in hypertensive crisis. Lancet. 1985;2(8445):34-35.
  191. van Vliet AA, Hackeng WH, Donker AJ, Meuwissen SG. Efficacy of low-dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis. J Hepatol. 1992;15(1-2):40-47. doi:10.1016/0168-8278(92)90009-e [PubMed 1324274]
  192. Vandenburg M, Parfrey P, Wright P, Lazda E. Hepatitis associated with captopril treatment. Br J Clin Pharmacol. 1981;11(1):105-106. doi:10.1111/j.1365-2125.1981.tb01116.x [PubMed 7011347]
  193. Varon J, Elliott W. Management of severe asymptomatic hypertension (hypertensive urgencies) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 19, 2022.
  194. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Arch Intern Med. 1984;144(10):1947-1953. [PubMed 6237623]
  195. von Vigier RO, Mozzettini S, Truttmann AC, et al. Cough is common in children prescribed converting enzyme inhibitors. Nephron. 2000;84(1):98. [PubMed 10644922]
  196. Weber MA. Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors. Am J Med. 1988;84(4A):16-23. doi:10.1016/0002-9343(88)90465-2 [PubMed 3064605]
  197. Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? Am J Hypertens. 1999;12(12 Pt 3):195S-203S. doi:10.1016/s0895-7061(99)00104-1 [PubMed 10619572]
  198. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531-548. doi:10.2215/CJN.07821109 [PubMed 20150448]
  199. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115. [PubMed 29133356]
  200. White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy. 1998;18(3):588-599. [PubMed 9620109]
  201. Winfred RI, Nanda S, Horvath G, Elnicki M. Captopril-induced toxic epidermal necrolysis and agranulocytosis successfully treated with granulocyte colony-stimulating factor. South Med J. 1999;92(9):918-920. doi:10.1097/00007611-199909000-00015 [PubMed 10498172]
  202. Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2010;20(9):532-536. doi:10.1097/FPC.0b013e32833d3acb [PubMed 20625347]
  203. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
  204. Wu VC, Kuo CC, Chang HW, et al. Diagnosis of primary aldosteronism: comparison of post-captopril active renin concentration and plasma renin activity. Clin Chim Acta. 2010;411(9-10):657-663. [PubMed 20117105]
  205. Yeo WW, Chadwick IG, Kraskiewicz M, Jackson PR, Ramsay LE. Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P. Br J Clin Pharmacol. 1995;40(5):423-429. [PubMed 8703645]
  206. Yusuf S, Sleight P, Pogue J, et al; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 [PubMed 10639539]
Topic 9196 Version 509.0